Spero Therapeutics annual ebitda
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Spero Therapeutics EBITDA Growth & History (SPRO)
Spero Therapeutics's calculated EBITDA was $6.3M for fiscal 2025.
View full Spero Therapeutics company overviewSpero Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $6.3M | $79.7M | — |
| 2024 | 2024-12-31 | −$73.4M | −$95.2M | — |
| 2023 | 2023-12-31 | $21.8M | $63.2M | — |
| 2022 | 2022-12-31 | −$41.3M | $46.0M | — |
| 2021 | 2021-12-31 | −$87.3M | −$9.0M | — |
| 2020 | 2020-12-31 | −$78.4M | −$15.9M | — |
| 2019 | 2019-12-31 | −$62.5M | −$20.1M | — |
| 2018 | 2018-12-31 | −$42.4M | −$1.0M | — |
| 2017 | 2017-12-31 | −$41.4M | −$8.4M | — |
| 2016 | 2016-12-31 | −$32.9M | −$19.6M | — |
| 2015 | 2015-12-31 | −$13.3M | — | — |
Spero Therapeutics quarterly ebitda
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q3.25
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q3 2025 | 2025-09-30 | −$7.9M | $6.1M | — |
| Q4 2024 | 2024-12-31 | −$21.7M | −$72.3M | — |
| Q3 2024 | 2024-09-30 | −$18.6M | −$16.8M | — |
| Q2 2024 | 2024-06-30 | −$19.1M | −$6.3M | — |
| Q1 2024 | 2024-03-31 | −$14.0M | $132,000 | — |
| Q4 2023 | 2023-12-31 | $50.6M | $24.5M | +94.10% |
| Q3 2023 | 2023-09-30 | −$1.8M | $9.8M | — |
| Q2 2023 | 2023-06-30 | −$12.8M | $13.0M | — |
| Q1 2023 | 2023-03-31 | −$14.1M | $15.9M | — |
| Q4 2022 | 2022-12-31 | $26.1M | $53.4M | — |
| Q3 2022 | 2022-09-30 | −$11.6M | $10.8M | — |
| Q2 2022 | 2022-06-30 | −$25.8M | −$7.4M | — |
| Q1 2022 | 2022-03-31 | −$30.0M | −$10.8M | — |
| Q4 2021 | 2021-12-31 | −$27.3M | −$8.7M | — |
| Q3 2021 | 2021-09-30 | −$22.4M | −$3.5M | — |
| Q2 2021 | 2021-06-30 | −$18.4M | −$108,000 | — |
| Q1 2021 | 2021-03-31 | −$19.2M | $3.4M | — |
| Q4 2020 | 2020-12-31 | −$18.6M | $7.4M | — |
| Q3 2020 | 2020-09-30 | −$18.8M | −$1.3M | — |
| Q2 2020 | 2020-06-30 | −$18.3M | −$4.8M | — |
| Q1 2020 | 2020-03-31 | −$22.6M | −$17.1M | — |
| Q4 2019 | 2019-12-31 | −$26.0M | −$15.0M | — |
| Q3 2019 | 2019-09-30 | −$17.5M | −$6.6M | — |
| Q2 2019 | 2019-06-30 | −$13.5M | −$3.6M | — |
| Q1 2019 | 2019-03-31 | −$5.5M | $5.2M | — |
| Q4 2018 | 2018-12-31 | −$10.9M | $3.0M | — |
| Q3 2018 | 2018-09-30 | −$10.9M | −$982,000 | — |
| Q2 2018 | 2018-06-30 | −$9.9M | $205,000 | — |
| Q1 2018 | 2018-03-31 | −$10.7M | −$3.2M | — |
| Q4 2017 | 2017-12-31 | −$13.9M | — | — |
| Q3 2017 | 2017-09-30 | −$9.9M | — | — |
| Q2 2017 | 2017-06-30 | −$10.1M | — | — |
| Q1 2017 | 2017-03-31 | −$7.5M | — | — |
Spero Therapeutics ebitda trends
Over the last five reported fiscal years, Spero Therapeutics's ebitda increased from −$78.4M to $6.3M, a change of $84.7M. The latest reported quarter, Q3 2025, shows −$7.9M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Spero Therapeutics filings at SEC.gov ↗